Method for the production of modified steroid degrading microorganisms and there use

van der Geize, Robert; Hessels, Gerda I.; Dijkhuizen, Lubbert

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Publication date:
2009

Citation for published version (APA):
van der Geize, R., Hessels, G. I., & Dijkhuizen, L. (2009). *Method for the production of modified steroid degrading microorganisms and there use.* (Patent No. *WO2009024572*).

(19) **United States**

(12) **Patent Application Publication**   (10) Pub. No.: **US 2009/0186390 A1**
   van der Geize et al.   (43) **Pub. Date:**   **Jul. 23, 2009**

(54) **METHOD FOR THE PRODUCTION OF MODIFIED STEROID DEGRADING MICROORGANISMS AND THEIR USE**

(75) Inventors: **Robert van der Geize**, Veendam (NL); **Gerda Hessels**, Groningen (NL); **Lubbert Dijkhuizen**, Zuidlaren (NL)

Correspondence Address:
ORGANON USA, INC.
c/o Schering-Plough Corporation
2000 Galloping Hill Road, Mail Stop: K-6-1, 1990
Kenilworth, NJ 07033 (US)

(73) Assignee: **N.V. Organon**

(21) Appl. No.:   **12/194,903**

(22) Filed: **Aug. 20, 2008**

Related U.S. Application Data

(60) Provisional application No. 60/957,030, filed on Aug. 21, 2007.

Publication Classification

(51) **Int. Cl.**
     C12P 15/00   (2006.01)
     C12N 15/01   (2006.01)
     C12N 1/20   (2006.01)
     C07K 14/00   (2006.01)
     C07H 21/02   (2006.01)

(52) **U.S. Cl.** **435/127**; 435/448; 435/252.1; 530/350; 536/23.1

(57)   **ABSTRACT**

A method is described to construct genetically modified strains of steroid degrading micro-organisms wherein the method comprises inactivation of at least one gene involved in methylhexahydroindanedione propionate degradation. Strains with (multiple) inactivated steroid degrading enzyme genes according to the invention can be used in the accumulation of steroid intermediates. Accumulation products are for example 3aα-H-4α(3'-propionic acid)-7aβ-methylhexahydro-1,5-indanedione (HIP), 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione (3-HSA), 1,4-androstadiene-3,17-dione (ADD) and 3aα-H-4α(3'-propionic acid)-5α-hydroxy-7aβ-methylhexahydro-1-indanone-δ-lactone (HIL).

FIG. 1

FIG. 2

FIG. 3

FIG. 4A

FIG. 4B

FIG. 4C

METHOD FOR THE PRODUCTION OF MODIFIED STEROID DEGRADING MICROORGANISMS AND THEIR USE

[0001] This application is a non-provisional application that claims priority under 35 U.S.C. § 119(e) of provisional application U.S. Ser. No. 60/957,030 filed Aug. 21, 2007, the contents of which are hereby incorporated by reference in its entirety.

[0002] The invention relates to a method to prepare genetically modified micro-organisms having inhibited capacity for nucleus degradation of steroids, to the use of such micro-organism in steroid accumulation as well as to said modified micro-organisms.

[0003] The ability to degrade steroids is widespread in actinobacteria and requires a set of enzymes degrading the side-chain and the steroid nucleus structure. *Rhodococcus* species are well-known in the art for their large catabolic potential. Several *Rhodococcus* species are able to degrade natural phytosterols, which are inexpensive starting materials for the production of bioactive steroids. For instance, it is known that *Rhodococcus* strains treated with mutagens and/or incubated with enzyme inhibitors convert sterols into 4-androstene-3, 17-dione and 1,4-androstadiene-3,17-dione.

It is further known, that methylhexahydroindanedione propionate (HIP; 3aα-H-4α(3'-propionic acid)-7aβ-methyl-hexahydro-1,5-indanedione) and 5-hydroxy-methylhexahydroindanone propionate (HIL; 3aα-H-4α(3'-propionic acid)-5α-hydroxy-7aβ-methylhexahydro-1-indanone-δ-lactone) are formed during the microbial degradation of steroids and sterols by actinobacteria (FIG. 1), e.g. by *Rhodococcus equi, Nocardia restricta, Nocardia corallina, Streptomyces rubescens* and *Mycobacterium fortuitum*. Reportedly, HIL formation has also been observed during deoxycholic acid degradation by *Pseudomonas* sp.

HIP and HIL are valuable staring compounds for the synthesis of medically important steroids, such as 19-norsteroids.

[0004] Previous studies have shown that in the steroid catabolic pathway, degradation of intermediate HIP presumably occurs via a β-oxidation mechanism. The first step in H P degradation in *Rhodococcus equi* is assumed to be an ATP-dependent CoA activation of HIP, followed by a reduction of the 5'-keto moiety of HIP-CoA by a HIP-reductase, resulting in the formation of HIL-CoA (FIG. 1). Further it is known from literature that in HIP degradation CoA activation is a prerequisite prior to reduction. Microbial CoA-transferases are usually comprised of two pairs of α and β subunits, forming an $\alpha_2\beta_2$ enzyme complex, encoded by two separate genes. The crystal structure of glutaconate CoA transferase of *Acidaminococcus fermentans* has been solved and reported in literature, and further a glutamate residue in the β subunit of glutaconate CoA transferase of *A. fermentans* and propionate CoA transferase of *Clostridium propionicum* has been identified as catalytic residue.

Recently, two gene clusters involved in testosterone degradation have been identified in *Comamonas testosteroni* TA441, one of which contains ORFs suggested to be involved in HIP degradation (Horinouchi, M. et al. *Microbiology* 147: 3367-3375 (2001), and *Biochem Biophys Res Comm* 324: 597-604 (2004)). The specific genes for HIP degradation, however, are not known.

[0005] The present invention relates to the identification of three genes in *Rhodococcus erythropolis* SQ1 involved in methylhexahydroindanedione propionate degradation (ipd); two of these genes encode a HIP CoA transferase (ipdA and ipdB), and one gene encodes a putative HIL-(3'α-hydroxypropionyl)-CoA dehydrogenase (ipdF). According to one aspect of the present invention the nucleotide sequences of the ipdA gene, ipdB gene and ipdF gene of *R. erythropolis* SQ1 have been provided as a gene cluster (SEQ ID NO:1). The present invention also includes DNA sequences comprising nucleotides 1814-2722 of SEQ ID NO:1 (ipdA), nucleotides 2719-3474 of SEQ ID NO:1 (ipdB), and nucleotides 927-13 of SEQ ID NO:1 (ipdF). Furthermore, the present invention includes an IpdA protein comprising the amino acid sequence SEQ ID NO:3 or orthologues therefrom, an IpdB protein comprising the amino acid sequence SEQ ID NO:5 or orthologues therefrom, and an IpdF protein comprising the amino acid sequence SEQ ID NO:7 or orthologues therefrom. Preferably these orhologues belong to the genus *Rhodococcus* but also related genera belonging to the family of Actinomycetes, such as *Nocardia, Corynebacterium, Mycobacterium*, and *Arthrobacter*, can be used. More particularly, the ipdA protein is encoded by nucleotides 1814-2722 of SEQ ID NO:1. The ipdB protein is encoded by nucleotides 2719-3474 of SEQ ID NO:1. The ipdF protein is encoded by nucleotides 927-13 of SEQ ID NO:1.

[0006] Finally, the invention includes DNA sequences encoding the above-mentioned IpdA protein, IpdB protein, and an IpdF protein.

[0007] Primarily, the present invention relates to a method to construct a genetically modified strain of a steroid-degrading micro-organism, wherein the method comprises inactivation of at least one gene involved in methylhexahydroindanedione propionate degradation. In particular, the method comprises inactivation of multiple genes D involved in methylhexahydroindanedione propionate degradation. Another embodiment of the invention relates to a method wherein at least one gene encoding a HIP CoA transferase is inactivated, and particularly wherein the HIP CoA transferase genes ipdA, encoding the α-subunit of HIP CoA transferase, and ipdB, encoding the β-subunit of HIP CoA transferase, are inactivated.

A further embodiment relates to a method to construct a genetically modified strain of a steroid-degrading micro-organism wherein a gene encoding a HIL-(3'α-hydroxypropionyl)-CoA dehydrogenase (ipdF) is inactivated.

[0008] Still another embodiment is a genetically modified micro-organism wherein at least one gene involved in methylhexahydroindanedione propionate degradation has been inactivated according to the present invention. Preferred are micro-organisms belonging to the family of *Actinomycetes*. More preferred are micro-organisms belonging to the genus *Rhodococcus*. Most preferred embodiments are the strains *Rhodococcus erythropolis* RG37 and *Rhodococcus erythropolis* RG33.

The micro-organism strains *Rhodococcus erythropolis* RG37 and *Rhodococcus erythropolis* RG33 have been deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig, Germany under the accession numbers DSM 18157 and DSM 18156 respectively. These deposits have been made under the terms of the Budapest Treaty.

[0009] According to another aspect of the present invention micro-organisms possessing gene inactivation according to the present invention can be used in the preparation of intermediates of the steroid catabolic pathway by accumulation

thereof. When 9α-hydroxy-4-androstene-3,17-dione (9OHAD) is incubated with a mutant strain in which HIP CoA transferase is inhibited (e.g. by inactivation of the ipdAB genes) accumulation of HIP occurs, a starting material for the synthesis of 19-norsteroids. Also, in this conversion 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione (3-HSA) is formed as accumulation product. Therefore, another embodiment of the present invention is the use of a genetically modified strain of a micro-organism wherein the ipdAB genes are inactivated according to the present invention, in the preparation of 3aα-H-4α(3'-propionic acid)-7aβ-methylhexahydro-1,5-indanedione (HIP) and/or 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione (3-HSA) by growing said strain on a culture medium comprising 9OHAD. Another embodiment of the invention relates to the use of a genetically modified strain of a micro-organism wherein the ipdAB genes are inactivated according to the invention, in the preparation of 1,4-androstadiene-3,17-dione (ADD) by growing said strain on a culture medium comprising 4-androstene-3,17-dione (AD).

[0010] A further embodiment of the present invention is the use of a genetically modified strain of a micro-organism wherein the ipdF gene is inactivated according to the present invention, in the preparation of HIL by growing said strain on a culture medium comprising AD. Another embodiment is the use of a genetically modified strain of a micro-organism wherein the ipdF gene is inactivated according to the present invention, in the preparation of 3aα-H-4α(3'-propionic acid)-7aβ-methylhexahydro-1,5-indanedione (HIP) and/or 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione (3-HSA) by growing said strain on a culture medium comprising 9OHAD.

[0011] Inactivation of genes is a powerful tool for analysis of gene function and for introduction of metabolic blocks. Gene disruption with a non-replicative vector carrying a selective marker is the commonly used method for gene inactivation. Construction of strains with desirable properties via metabolic pathway engineering approaches, however, may require the stepwise inactivation or replacement of several genes. This is only possible when a suitable strategy for introduction of unmarked gene deletions or gene replacements, allowing infinite rounds of metabolic engineering without being dependent on multiple markers, is available. Methods for introduction of unmarked gene deletions in actinobacteria, in particular in the genus *Rhodococcus* have been reported e.g. in WO 01/31050.

[0012] An advantage of unmarked mutation is that it allows the repetitive introduction of mutations in the same strain. Foreign DNA (vector DNA) is removed in the process of introducing the mutation. Newly introduced vector DNA, for the introduction of a second mutation, therefore cannot integrate at the site of the previous mutation (by homologous recombination between vector DNA's). Integration will definitely happen if vector DNA is still present in the chromosome and will give rise to a large number of false-positive integrants. The system enables the use of a sole antibiotic gene for the introduction of an infinite number of mutations. Unmarked mutation also allows easy use in the industry because of the absence of heterogeneous DNA allowing easy disposal of fermentation broth.

Gene inactivation by gene deletion enables the construction of stable, non-reverting mutants. Especially small genes (<500 bp) are inactivated more easily by gene deletion compared to gene disruption by a single recombination integra-

tion. Gene deletion mutagenesis can also be applied to inactivate a cluster of several genes from the genome. The gene deletion mutagenesis strategy can be applied also for gene-replacement (e.g. changing wild type into mutant gene).

[0013] The preferred strain for mutagenesis of the catabolic steroid ipd genes is *Rhodococcus erythropolis*. However, unmarked gene deletion of similar genes in other species, genetically accessible by e.g. conjugation or electrotransformation, is conceivable if the molecular organization is the same (or similar) as in *R. erythropolis* SQ1. Preferably these species belong to the genus Rhodococcus but also related genera belonging to the family of Actinomycetes, such as *Nocardia, Mycobacterium*, and *Arthrobacter*, can be used.

[0014] As a further embodiment of the present invention, for further gene inactivation, the same methods may be used again, or, alternatively, UV irradiation or chemical means such as nitroguanidine or diepoxyethaan may be used. Methods to introduce gene mutations in that way are well known in the art.

Also, methods to construct vehicles to be used in the mutagenesis protocol are well known (Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, latest edition). Furthermore, techniques for site directed mutagenesis, ligation of additional sequences, PCR, sequencing of DNA and construction of suitable expression systems are all, by now, well known in the art. Portions or all of the DNA encoding the desired protein can be constructed synthetically using standard solid phase techniques, preferably to include restriction sites for ease of ligation.

Modifications and variations of the method for introducing disrupted gene mutations or unmarked gene deletion as well as transformation and conjugation will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to come within the scope of present application.

LEGENDS TO THE FIGURES

[0015] FIG. 1. Scheme showing the proposed sterol/steroid (AD and cholesterol) catabolic pathways of *R. erythropolis* SQ1 and degredation of the HIP propionate side chain by β-oxidation. The ipd genes putatively involved in HIP degradation are indicated between brackets. The ipdAB genes, encoding the HIP-CoA transferase, and ipdF, encoding the HIL-(3'α-hydroxypropionyl)-CoA dehydrogenase, were deleted in parent strain SQ1, resulting in strain RG 37 and strain RG 33 respectively. The kshAB genes encode the two-component enzyme system 3-ketosteroid 9α-hydroxylase (KSH). The kshB gene is involved in both cholesterol and AD degradation (van der Geize R. et al.: *Mol. Microbiol.* 45:1007-1018 (2002)). The kstD and kstD2 genes encode 3-ketosteroid Δ1-dehydrogenases (van der Geize et al.: *Microbiology* 148: 3285-3292 (2002)).

[0016] FIG. 2. Schematic overview of an 11 kb genomic DNA fragment of *R. erythropolis* strain SQ1, containing the ipd gene cluster. Also shown are several pRESQ derived constructs (Table 1) used in functional complementation experiments of HIL growth deficient UV-mutant strains AP10 and AP20. PCR primers used to construct gene deletion mutant RG37 are indicated as P1-P4. IpdF-F and IpdF-R are PCR primers used to check ipdF gene deletion in RG33.

[0017] FIG. 3. Degradation of HIL (0.5 mg•mL^{-1}) in glucose (20 mM) mineral medium by parent strain SQ1 (closed

circles), ipdAB mutant strain RG37 (triangles) and ipdF mutant strain RG33 (open circles).

[0018] FIG. 4. Gas chromatograms of samples taken 72 h after addition of AD, 9OHAD or HIP from cultures of (A) ipdAB mutant strain RG37, (B) ipdF mutant strain RG33 and (C) parent strain SQ1, following growth to late exponential phase in glucose (20 mM) mineral medium. Numbers above peeks indicate the following compounds: 1, HIP; 2 HIP; 3, AD; 4, 3-HSA; 5, ADD. Identities of compounds were verified using authentic samples.

[0019] A person skilled in the art will understand how to use the methods and materials described and referred to in this document in order to construct micro-organisms according to the present invention.

The following examples are illustrative for the invention and should in no way be interpreted as limiting the scope of the invention.

EXAMPLES

[0020] (A) Isolation of UV-induced Mutants of *R. erythropolis* SQ1 Blocked in HIL Degradation

HIL growth deficient mutants (HIL⁻) of *R. erythropolis* SQ01 growing well on mineral glucose agar plates, were selected following UV mutagenesis. Mutants with a glucose⁺/HIL⁻ growth phenotype were selected. Bioconversion experiments were subsequently performed to identify mutants that were blocked in the first step of HIL degradation. It was found that mutant AP10 degraded HIL very slowly, while mutant AP20 was completely blocked in HIL degradation. Strains AP10 and AP20 were selected for functional complementation with a genomic library of *R. erythropolis* to identify the genes encoding the first steps in HIL degradation.

(B) Molecular Characterization of the ipd Gene Cluster Following Functional Complementation of HIL Growth Negative Mutants AP10 and AP20

[0021] A genomic library of *R. erythropolis*, constructed in the *Rhodococcus-E. coli* shuttle vector pRESQ (van der Geize R. et al.: *Mol Microbiol.* 45:1007-1018 (2002)), was introduced into mutant strains AP10 and AP20 to complement its mutant HIL⁻ growth phenotype. This resulted in the isolation of two plasmids, pAR1 and pAR2000, that were able to restore growth of AP10 and AP20, respectively. Attempts for cross-complementation, introducing pAR1 into mutant AP20 and pAR2000 into mutant AP10, did not restore growth on HIL mineral agar plates, indicating that different genes had been inactivated in these two mutants (FIG. 2). Restriction analysis of pAR1 and pAR2000 confirmed the uniqueness of both plasmids, revealing different restriction patterns. Subsequent nucleotide sequence analysis revealed overlap of approximately 0.2 kb between both plasmids, resulting in a total contiguous sequence of about 11 kb (GC content, 62.1%). The contiguous DNA sequence revealed a total number of 10 ORFs. Database similarity searches indicated that several genes were homologous to genes involved in β-oxidation.

The genes were tentatively designated ipdA to ipdH, because of their expected involvement in methylhexahydroindanedione propionate degradation (Table 2, FIGS. 1 and 2). The ipdABH genes appear to be translationally coupled (ATGA start-stop codons), probably comprising an operon. This operon most likely includes the ipdE gene as well, since the start codon of ipdA is separated by only 7 nt from the stop

codon of ipdE. The putative ipdEABH operon structure is highly conserved among many actinomycetes and, to a lesser extent, in *C. testosteroni* TA441.

(C) Molecular Characterization and Unmarked In-frame Gene Deletion Indicate that ipdAB Encode a CoA-transferase Involved in HIP and HIL Degradation

A series of sub-clones of pAR1 were constructed in pRESQ in order to determine which genes had been inactivated by the UV treatment in mutant AP10 (FIG. 2). A 2.8 kb DNA fragment of the insert of pAR1 (FIG. 2), carrying ipdA and ipdB as intact genes, was cloned into pRESQ (pAR10, Table 1, FIG. 2) and introduced into AP10. This fragment could functionally complement mutant AP10, indicating that either ipdA or ipdB had become inactivated in AP10. The ipdA and ipdB genes encode proteins of 302 amino acids (ipdA, Mw 33.2 kDa) and 251 amino acids (IpdB, Mw 27.1 kDa), respectively. Database similarity searches revealed that IpdA contains the Pfam01144 signature of Coenzyme A transferases (http://www.sanger.ac.uk/Software/Pfam/) as well as the COG1788 signature (http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml) of AtoD, the α subunit of acyl CoA: acetate/3-ketoacid CoA transferase of *E. coli*. IpdB furthermore contains the COG2057 signature of AtoA, the β subunit of acyl CoA:acetate/3-ketoacid CoA transferase of *E. coli*. IpdA and IpdB also share amino acid sequence similarity with GctA (25% identity, Mw 35.7 kDa) and GctB (25% identity, Mw 29.2 kDa), the α and β subunits of glutaconate CoA-transferase of *A. fermentans*, respectively (Mack M. et al.: *Eur. J. Biochem.* 226: 41-51 (1994)). Thus, IpdA and IpdB encode the α and β subunit of a CoA-transferase involved in HIL degradation.

(D) Construction of Mutant RG37

[0022] An unmarked ipdAB gene deletion mutant of parent *R. erythropolis* strain SQ1 was constructed to confirm the involvement of ipdAB in HIL degradation. This mutant, designated *R. erythropolis* strain RG37, was constructed using mutagenic plasmid pAR31 via the sacB counter-selection method (van der Geize et al.: *FEMS Microbiol. Lett.* 205:197-202 (2001)). Simultaneous gene deletion of both ipdA and ipdB resulted in a single in-frame ORF remnant of 249 nt in the genome of RG37, encoding the first 46 amino acids of IpdA and the last 36 amino acids of IpdB. Gene deletion was confirmed by PCR using the P1 forward and P4 reverse primers (FIG. 2). Using these primers, PCR products of 1.56 kb and 2.96 kb were found with genomic DNA of mutant strain RG37 and parent strain SQ1, respectively.

(E) Degradation of HIL using Mutant Strain RG37 as Compared to Parent Strain SQ1

Inactivation of the ipdAB genes rendered mutant strain RG37 unable to grow on mineral agar medium supplemented with HIL or HIP as sole carbon and energy source, confirming the involvement of ipdAB in HIL and HIP degradation. Incubation of HIL (0.5 g•L⁻¹) with parent strain SQ1 resulted in a substantial degradation of HIL over a period of five days (FIG. 3). However, no degradation of HIL was observed after 5 days in bioconversion experiments with mutant strain RG37 (FIG. 3). The ipdAB genes thus encode the α and β subunits, respectively, of a HIL CoA transferase, the first step in HIL degradation.

(F) Inactivation of ipdAB Results in Impaired Hydroxylation of Steroid Catabolic Pathway Intermediates

Since HIP and HIL are expected intermediates in steroid degradation (FIG. 1), we studied the ability of mutant strain

RG37 to grow on 4-androstene-3,17-dione (AD), 9α-hydroxy-4-androstene-3,17-dione (9OHAD) and cholesterol. Growth of strain RG37 in mineral medium supplemented with either AD, 9OHAD or cholesterol revealed that RG37 was unable to grow on these steroid substrates as sole carbon and energy sources.

We subsequently studied the biotransformation of AD by cultures of RG37 grown to late exponential phase in glucose mineral medium. Strain RG37 was able to partly convert AD into ADD, resulting from 3-ketosteroid Δ1-dehydrogenase (KSTD) activity (van der Geize et al.: *Appl. Environ. Microbiol.* 66: 2029-2036 (2000) and *Microbiology* 148: 3285-3292 (2002), FIG. 1). However, AD and ADD were not degraded further and HIP or HIL formation was not observed (FIG. 4A). These results showed that the ipdAB gene deletion had a suppressive effect on AD/ADD 9α-hydroxylation. The mutant phenotype of strain RG37 is similar to the 3-ketosteroid 9α-hydroxylase (KSH) negative mutant phenotypes of the kshA and kshB mutant strains *R. erythropolis* RG2 and strain RG4, respectively, we previously described (van der Geize R. et al.: *Mol. Microbiol.* 45:1007-1018 (2002)). The kshA and kshB genes encode the terminal oxygenase component (KshA) and oxygenase-reductase component (KshB) of KSH, respectively, involved in 9α-hydroxylation of AD (forming 9OHAD) and 4-cholestene-3-one. The kshB gene deletion mutant strain RG4 is blocked in 9α-hydroxylation of AD, ADD and 4-cholestene-3-one. Thus, inactivation of ipdAB apparently impairs KSH enzyme activity in *R. erythropolis* SQ1. Biotransformation of 9α-hydroxylated AD (9OHAD) with mutant strain RG37 resulted in degradation of 9OHAD and the accumulation of intermediates identified as 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione (3-HSA) and HIP (FIG. 4A). The accumulation of 3-HSA from 9OHAD was interesting and indicated that also 4-hydroxylation of 3-HSA, the proposed next step in 3-HSA degradation (Horinouchi, M. et al.: *Biochem Biophys Res Comm* 324: 597-604 (2004), was impaired by the ipdAB deletion. Deletion of the ipdAB genes thus appears to have a marked inhibitory effect on steroid degradation, particularly on the hydroxylation of pathway intermediates, explaining why growth is not observed with strain RG37 using AD and 9OHAD as sole carbon and energy sources. As stated earlier, strain RG37 is also unable to grow on cholesterol as sole carbon and energy source, which is likely due to suppression of 9α-hydroxylation of 4-cholestene-3-one blocking further degradation.

Based on these results we conclude that the ipdAB genes encode the α and β subunit of a CoA transferase with activity towards HIP and HIL. Since HIP is the expected actual substrate of the ipdAB encoded enzyme in the steroid degradation to pathway (FIG. 1), the name HIP CoA-transferase is used.

(G) Molecular Characterization and Unmarked Gene Deletion of ipdF Suggests that IpdF is a HIL-(3'α-hydroxypropionyl)-CoA Dehydrogenase

A set of sub-clones of plasmid pAR2000 in pRESQ was introduced into UV mutant AP20 in order to identify the gene inactivated in this mutant (FIG. 2), A 1.9 kb DNA fragment of the insert of pAR2000 (pAR2010: Table 1, FIG. 2) was still able to functionally complement the AP20 phenotype. The ipdF gene was the sole intact gene on this DNA fragment. We thus concluded that ipdF had been inactivated in the AP20 mutant.

[0023] The ipdF gene encodes a protein (IpdF) of 304 amino acids (31.1 kDa). Analysis of the amino acid sequence revealed the presence of a Pfam00106 signature of the short chain dehydrogenase/reductase (SDR) superfamily. Moreover, IpdF contains the glycine motif (Gx(3)GxG (amino acids 14-20) and the Yx(3)K motif (amino acids 171-175) typical for classical SDR proteins (Kallberg et al.: *Eur. J. Biochem* 269: 4409-4017 (2002)). The highest similarities (71% identity, 82% similarity) were found with hypothetical proteins of the SDR superfamily from several actinomycetes, as well as with ORF27 (53% identity, 68% similarity) of *C. testosterone* TA 441 (Horinouchi, M. et al.; *Microbiology* 147; 3367-3375 (2001) and *Biochem Biophys Res Comm* 324;

[0024] 597-604 (2004)) In all these bacteria, the genomic location of the corresponding gene was in close proximity to the location of their ipdAB gene orthologues. IpdF furthermore has extensive similarity (37% identity) with the N-terminal (amino acids 1-323) part of mammalian 17β-hydroxysteroid dehydrogenase IV (HSD17B4; Leenders et al.; *Eur. J. Biochem,* 222; 221-227 (1994)), also known as peroxisomal multifunctonal protein 2 (MFP-2; Dieuaide-Noubhani et al.; *Biochem. J.* 325; 367-73 (1997)). As the name implies, HSD17B4/MFP-2 is a multifunctional protein (737 amino acids, 80 kDa) exhibiting several enzymatic activities. The N-terminal portion of HSD17B4/MFP-2 is cleaved off as a 32 kDa enzyme, having 17β-hydroxysteroid dehydrogenase and 3-hydroxyacyl-CoA dehydrogenase activities (Adamski et al.: *Steroids* 62: 159-163 (1997)). Based on these similarities it is assumed that IpdF is the HIL-(3'α-hydroxypropionyl)-CoA dehydrogenase involved in β-oxidation of the propionate side chain of HIL (FIG. 1).

(H) Construction of Mutant RG33

[0025] An ipdF gene deletion mutant strain RG33 was constructed from *R. erythropolis* SQ1 to confirm the involvement of IpdF in HIP, HIL, and steroid degradation. An internal DNA fragment (0.43 kb) of wild type ipdF gene (915 bp) was deleted (FIG. 2) using pAR2015 (Table 1; see "Experimental procedures" section) as mutagenic plasmid. Following ipdF gene deletion, a frame-shifted ORF remnant of 484 bp, encoding a nonsense protein of 98 amino acids, was introduced, Genuine ipdF gene deletion was confirmed by PCR using ipdF forward (IpdF-F) and reverse (IpdF-R) primers (see "Experimental procedures" section). A PCR product of 499 bp was found with genomic DNA isolated from mutant strain RG33, compared to a 930 bp PCR fragment for wild type ipdF with genomic DNA isolated from parent strain SQ1.

(I) Degradation of HIL using Mutant Strain RG33

[0026] Mutant strain RG33 was unable to grow on mineral medium supplemented with HIL (0.5 g•L^{-1}) or HIP (0.5 g•L^{-1}) as sole carbon and energy source. Moreover, degradation of HIL (0.5 g•L^{-1}) was impaired and HIL concentrations decreased more slowly in biotransformation experiments with RG33 over a period of 5 days compared to wild type (FIG. 3).

(J) Inactivation of ipdF Results in HIL Accumulation from AD

Strain RG33 was also not able to grow in mineral liquid medium supplemented with AD, 9OHAD or cholesterol as sole carbon and energy sources, Biotransformation of AD by liquid cultures of strain RG33 grown to late exponential phase in glucose mineral medium revealed that, in contrast to strain RG37, 9α-hydroxylation was not impaired and accumulation

5

of HIL from AD occurs (FIG. **4**B). Incubation of RG33 cultures with 9OHAD on the other hand. resulted in the accumulation of 3-HSA, HIP and HIL, indicating that degradation of 9OHAD was affected by ipdF inactivation. The accumulation of the expected substrate of IpdF, HIL-(3'α-hydroxypropionyl) [3OH-HIL], could not be verified with authentic 3OH-HIL. Authentic 3OH-HIL could not be obtained from a commercially source nor synthesized easily. However, the high similarity of ipdF to 3-hydroxyacyl-CoA dehydrogenase domain of mammalian HSD17B4/MFP-2 multifunctional protein in addition to the fact that ipdF is essential for growth on HIP/HIL strongly implies that ipdF encodes HIL-(3'α-hydroxypropionyl)-CoA dehydrogenase.

Experimental Procedures

(K) Bacterial Strains, Plasmids and Growth Conditions

[0027] Plasmids and bacterial strains used are listed in Table 1. *Rhodococcus* strains were cultivated at 30° C. and 200 rpm. Complex medium (LBP) contained 1% (wt/vol) bacto-peptone (Difco, Detroit, Mich.), 0.5% (wt/vol) yeast extract (BBL Becton Dickinson and Company, Cockeysville, Md.) and 1% (wt/vol) NaCl. Mineral medium (MM) consisted of 4.65 g L^{-1} K_2HPO_4, 1.5 g L^{-1} NaH_2PO_4 H_2O, 3 g L^{-1} NH_4Cl, 1 g L^{-1} $MgSO_4.7H_2O$, and Vishniac trace elements (pH 7). Filter sterilized glucose (20 mM) was added to autoclaved medium. Steroids, HIP, and HIL, supplied by Diosynth bv. (Oss, The Netherlands), were solubilized in DMSO (50 mg.mL^{-1}) and added to autoclaved medium to final concentration of 0.5 g.L^{-1} for growth experiments and 1 g.L^{-1} for biotransformation experiments. Cholesterol (1 g.L^{-1}, Sigma) was added as solid to mineral liquid medium, finely dispersed by sonication and subsequently autoclaved. Growth on mineral liquid media was followed spectrophotometrically (AD, 9OHAD, HIP, HIL) or by determination of total protein content of the culture (cholesterol, BioRad protein assay). Sucrose (Suc) sensitivity of *Rhodococcus* strains was tested on LBP agar supplemented with 10% (w/v) sucrose (LBPS). *E. coli* strains (Table 1) were grown in Luria-Bertani (LB) broth at 37° C. BBL agar (1.5% (wt/vol)) was added for growth on solid medium.

(L) General Cloning Techniques

[0028] DNA modifying enzymes were purchased from Boehringer (Mannheim, Germany). New England Biolabs (Beverly, Mass.) or Amersham Pharmacia Biotech AB (Uppsala, Sweden) and were used as described by the manufacturer. Isolation of DNA restriction fragments from agarose gels was done using the GeneClean II (Q-BIOgene, Carlsbad, Calif., USA) gel extraction kit according to protocol. All DNA manipulations were done according to standard protocols. PCR was performed under standard conditions using Expand polymerase (Boehringer) unless stated otherwise: 30 cycles of 1 min 95° C. 45 sec 60° C., 1,5 min 72° C. Genomic DNA isolation and colony PCR was performed as described (van der Geize et al.: *Appl. Environ. Microbiol.* 66: 2029-2036 (2000)) Transformation of *Rhodococcus* strains for unmarked gene deletion experiments was performed by mobilization of the mutagenic vector from *E. coli* S17-1 (Table 1) to the *Rhodococcus* strain by conjugation as described (van der Geize et al.: *FEMS Microbiol. Lett.* 205: 197-202 (2001)).

(M) UV Mutagenesis of *R. erythropolis* Strain SQ1
UV-induced mutagenesis essentially was done as previously described (van der Geize et al.: *FEMS Microbiol. Lett.* 205: 197-202 (2001)). HIL growth negative mutants, growing well on glucose mineral agar plates, but blocked in growth on mineral agar plates supplemented with 0.5 g.L^{-1} HIL, were selected for further work.
(N) Functional Complementation of *Rhodococcus* mutants AP10 and AP20
Electro-competent cells of mutant strains AP10 and AP20 were transformed with *R. erythropolis* genomic library (van der Geize et al., Mol Microbiol 45:1007-1018, (2002)). Transformations were replica plated onto HIL mineral agar plates (without antibiotic) for screening. Functional complementation of HIL growth negative mutants was observed after approximately 5 days. Plasmid DNA was isolated from the respective *Rhodococcus* tranformants and used for re-tranformation of the *Rhodococcus* mutants to check for genuine funstional complemetation by the isolated plasmid.

Bioconversion Experiments and Analysis by GC, HPLC and TLC

[0029] *R. erythropolis* parent strain SQ1 and mutants were grown in 50 mL glucose (20 mM) mineral medium for 2-3 days (OD$_{600}$>2). Steroids, HIP or HIL were added (1 g.L^{-1} final concentration) and bioconversion was followed during 5 days (in duplicate). Samples for GC and TLC analysis (0.5 mL) were acidified with 10 µl 10% H_2SO_4. Sample extraction was done using ethylacetate (2 mL). GC analysis was performed on a GC8000 TOP (Thermoquest Italia, Milan, Italy) with AT-5 MS column measuring 30 m by 0.25 mm (inner diameter) and a 0.25 µm film (Alltech, Ill., USA.) and FID detection at 300° C. Chromatographs obtained were analysed using Chromquest V 2.53 software (Thermoquest). For high-performance liquid chromatography (HPLC) analysis, samples were diluted five times with methanol-water (70:30) and filtered (0.45 µm). HPLC analysis was performed on a reversed-phase Lichrosorb 10RP18 (5u) column, measuring 250 by 4.6 mm (Varian Chrompack International, Middelburg, the Netherlands) with UV detection at 254 nm, and a liquid phase of methanol-water (60:40) at 30° C. TLC was done with Kieselgel 60 F_{254} 10×20 cm (Merck, Darmstadt, Germany) developed in toluene/ethylacetate 1:1.
(P) Construction of Mutagenic Plasmids pAR31 and pAR2015 for ipdAB and ipdF Unmarked Gene Deletion
For unmarked in-frame deletion of ipdA and ipdB, plasmid pAR31 (Table 1) was constructed. A 790 bp PCR fragment (PCR product 1), containing part of ipdE and the beginning of ipdA, was obtained using *R. erythropolis* SQ1 genomic DNA with P1 (XbaI) forward primer (5' GCGTCTAGACTGCGAGCCGAGGGACGCG 3'(SEQ ID NO:8)) and P2 (BamHI) reverse primer (5' GCGGGATC-CGTCCGAACGCAGAATCGCACG 3' (SEQ ID NO: 9)) (FIG. **2**). A second PCR fragment (800 bp, PCR product 2), containing the end of ipdB and part of ipdD, was amplified from *R. erythropolis* SQ1 genomic DNA with P3 (BamHI) forward primer (5' GCGGGATCCCTCGCCGAGGCCGG-TATCAC 3' (SEQ ID NO: 10)) and P4 (SmaI) reverse primer (5' GCGCCCGGGCTTGCGCGAGACCGTCGTATC 3' (SEQ ID NO: 11)). Underlined restriction sites, also indicated between brackets for each primer, were included in the four primers to ensure in-frame linkage of the ipdA start codon and the ipdB stop codon. PCR product 2 was cloned into SmaI digested pK18mobsacB (Table 1), resulting in plasmid

pAR30. Subsequently, PCR product 1 was digested with XbaI and BamHI and cloned into XbaI/BamHI digested pAR30, resulting in plasmid pAR31. For ipdF gene deletion, a 2.54 kb XhoI fragment of pAR2002 was cloned into pBlueScript II(KS), rendering pAR2013. The internal part (430 bp) of the ipdF gene was deleted by BclI/NcoI digestion of pAR2013 and blunt-ended self-ligation after Klenow treatment. The resulting plasmid (pAR2014) was digested with XhoI and a 2.11 kb DNA fragment. containing the ipdF deletion, was cloned into SalI digested pK18mobsacB, yielding plasmid pAR2015 used for ipdF gene deletion. Genuine ipdF gene deletion was checked by PCR with genomic DNA isolated from strain RG33 with IpdF-F forward primer (5'-ATA-CATATGAGTGGATTGGTCGACGGAC (SEQ ID NO : 12)) and IpdF-R reverse primer (5'-ATAGGATC-CCTACGCTCCGTACACCGGCGTC (SEQ ID NO: 13)).

TABLE 1

Strains and plasmids used in this study.

Strain or plasmid	Characteristics	Reference/origin
R. erythropolis SQ1	Parent strain, HIL⁺	Quan S. et al., Plasmid 29: 74-79 (1993)
R. erythropolis RG33	ipdF mutant of strain SQ1, HIL⁻	This study
R. erythropolis RG37	IpdAB mutant of strain SQ1, HIL⁻	This study
R. erythropolis AP10	UV-mutant of strain SQ1, HIL⁻	This study
R. erythropolis AP20	UV-mutant of strain SQ1, HIL⁻	This study
E. coli DH5α	Host for general cloning steps	Bethesda Res. Lab.
E. coli S17-1	Strain for conjugal mobilization of pK18mobsacB derivatives to *Rhodococcus* strains	Simon et al.: Biotechnology 1: 784-791 (1983)
pBlueScript(II) KS	bla lacZ	Stratagene
pK18mobsacB	aphII sacB oriT (RP4) lacZ	Schäfer et al.: Gene 145: 69-73 (1994)
pRESQ	*Rhodococcus-E. coli* shuttle vector	van der Geize R. et al.: Mol. Microbiol. 45: 1007-1018 (2002)
pAR1	pRESQ containing 5.2 kb genomic fragment of *R. erythropolis* carrying ipdA and ipdB	This study
pAR10	pRESQ carrying ipdA and ipdB on a 2.88 kb NcoI/HindIII fragment of pAR1 (HindIII located on cloning vector)	This study
pAR30	PCR product 2, obtained with primers P3 and P4 (FIG. 2), cloned in SmaI digested pK18mobsacB	This study
pAR31	PCR product 1, obtained with primers P1 and P2 (FIG. 2) cloned into XbaI/BamHI digested pAR30; used for ipdAB gene deletion in SQ1, yielding RG37	This study
pAR2000	pRESQ containing 6.1 kb genomic fragment of *R. erythropolis* carrying ipdF	This study
pAR2002	Self-ligation of 9.55 kb fragment of pAR2000 following Asp718I digestion	This study
pAR2003	Asp718I fragment (3.2 kb) of pAR2000 ligated into Asp718I digested pRESQ	This study
pAR2010	Self-ligation of Asp700I/Asp718I digested pAR2002 (blunt-ended with Klenow)	This study
PAR2013	2.54 kb XhoI fragment of pAR2002 cloned in XhoI site pBlueScript(II)KS	This study
pAR2014	Self-ligation of BclI/NcoI digested pAR2013 (5 kb, blunt-ended with Klenow)	This study
pAR2015	2.1 kb XhoI fragment of pAR2014 cloned in SalI site of pK18mobsac8; used for ipdF gene deletion in SQ1, yielding RG33	This study

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 13

<210> SEQ ID NO 1
<211> LENGTH: 4300
<212> TYPE: DNA
<213> ORGANISM: Rhodococcus erythropolis

<400> SEQUENCE: 1

gggccggagg ccctacgctc cgtacaccgg cgtcggaatc tccgccttct ccaacagcgt   60

tgccacgacg ggcccgatct ccttcgggtc ccaacggtca cccttgtcct cgctcgggcc   120

-continued

```
gtgacgccag ccctccgcga cggtgatctt tccgccctcg acctcgaaca cccgccccgt        180

gacgtccttg gactcggcgc taccgagcca gacgaccagc ggcgagatgt tctcgggcgc        240

catggcatcg aagccctctt cgggagctgc catcgactcg gccatcgccc cacccgcgcc        300

gacggtcatg cgcgtgcgcg cagcaggcgc gatcgcgttg acactgacgc cgtaattctt        360

gagctcggct gcggcctgga tggtcatctc ggcgataccg gccttcgccg cagcgtagtt        420

accctggccg atcgaacctt gcagtcctgc acccgaactg gtgttgatga tgcgtgcgtc        480

gacggtcttg cctgccttgg cctcagcgcg ccagtaggca gcagcgtgac gcagcggcgc        540

gaagtgcccc ttgaggtgca cgcgaatcac cgcgtccac tcgccttcgc tcatgccgac        600

cagcatgcgg tcccgcagga agcccgcgtt gttcacgagt acgtccaggc caccgaaggt        660

gtcgatcgcg tcttgatca gattctcggc gccgcccag tcggcgacgt cgtctccgtt        720

gaccactgct tggccaccgg cggcgatgat ctccgcgaca acctgctcgg ccggactctc        780

accggtctcg gaaccgtcgg cacccgcacc gatgtcgttg acgacgacct tggcgccctc        840

ggcagcaaac gccaaggcat gcgcacgtcc gatcccgcga ccagccccgg tgatgatgac        900

tacgcgtccg tcgaccaatc cactcatatt tgtctcctaa tgcactctgc tcgggcttgt        960

cggctccgct tgtgtgctaa cttaccaagc aatcgcttgg tttggtacac agacgtaagg       1020

aatcccgata tgggcatcag cacctcctcc gacggaaccg gcatcaccac ggtcaccatc       1080

gactacgcgc cggtcaatgc aatcccgtcc aagggatggt tcgagcttgc cgacgccatc       1140

ctcgacgcgg gcaaggatct caacactcac gtggtgatcc tgcgagccga gggacgcgga       1200

ttcaacgccg gcgtcgacat caaggagatg caggcgaccg agggattcga cgcactggtc       1260

gccgccaacc gcggttgcgc cgcgcgcctt cgcagccgtct acgactgcgc tgtaccgtc       1320

gtcgtggccg tcaacggatt ctgtgtcggc ggtggcatcg gactggtcgg caacgcggac       1380

gtgatcgtcg cttccgacga cgcgatcttc tccctccccg aggtcgaccg cggcgcactc       1440

ggcgctgcca cacacctctc acggctggtg ccgcagcaca tgatgcgcac gctctactac       1500

accgcacaga cgcgtcgacgc ccacacactc aaacagttcg gcagcgtcta cgacgtggtc       1560

ccgcgcgaga agctcgacga gtgcgctcgc gagatcgccg caaagatcgc cgcgaaggac       1620

acccgcatca tccggtgcgc caaggaagcc atcaacggca tcgacccggt cgacgtcaag       1680

ggcagctacc gcctcgagca gggctacacc ttcgaactca acctcctcgg tgtgtccgac       1740

gaacaccgcg acgaattcgt cgccaccggc aagccgcgcg agaacgcaac ccagaaggaa       1800

ggctgagaca aacatggcta gcaagcgtga caagacgaag tcgctcgacg aggtagtcgg       1860

cgagctccgc agcggaatga cgatcggctt gggcggctgg ggatctcgcc gcaagccgat       1920

ggccttcgtg cgtgcgattc tgcgttcgga catcaaggac ctgaccgtgg tcacttacgg       1980

cggaccggat ctcgggctgc tgtgctcggc cggcaaggtc aagaaggcgt actacggttt       2040

cgtgtccctg gactccgctc cgttctacga tccgtggttt gccaaggcac gcaccgccgg       2100

tgagatcgaa gtccgcgaga tggacgaggg aatggtcaag tgcggcctcg aagccgctgc       2160

cgctcgcctc cctttcctcc cgatccgcgc gggcctgggt tcggacgttc gcaacttctg       2220

gggcgacgaa ctcaagaccg tcacctcccc gtacccagag gccgacggcc gttccgagac       2280

cttgatcgcg atgcctgcac tcaacctcga tgcgtcgttc gttcacctca atctcggtga       2340

caagcacggc aatgccgcgt acaacggtgt cgacccgtac ttcgacgacc tgtactgcat       2400
```

-continued

```
ggccgccgaa aagcgttacg tctccgtcga acgcattgtc gagaccgagg aactggtcaa   2460

atccgttcca ctgcagaatc ttctgctcaa ccgcatgatg gtcgacgccg tcgtcgaggc   2520

cccgaacggt gcccacttca cgttggccgg cgaaagctac ggccgcgacg agaagttcca   2580

gcgtcactac gccgaggccg ccaagacccc cgagtcgtgg cagacgttcg tcgacacctt   2640

cctctccggc agcgaagagg actaccaagc cgcagtaaag aagtttgccg attcatcaaa   2700

ggcaggggag caggcaaaat gagcgaatcc accgtcaccc gcgcagagta cgttgttctc   2760

gcgtgcgctg aaatcttctc cggtgcaggc gaaatcatgg ccagcccgat gtcgacgtcg   2820

tccaccatcg gcgctcgcct ggctcggctc accaccgaac ccgacctgct gatcaccgat   2880

ggtgaagccc tcattctcga ggacaccccg gcagtcggaa cgaagggccc catcgaagga   2940

tggatgcctt ccgcaaggt gttcgacgtc gtcgcttcgg gccgtcgcca cgtagtcatg   3000

ggcgccaatc agctcgatcg ccacggcaac cagaacctct ccgccttcgg cccgcttcag   3060

cagccgacgc gtcagatgtt cggtgtgcgc ggcgccccgg gcaacaccat caaccacgcg   3120

acgagctact tcgtccccaa gcactccaag cgagtgttcg tcgacaaggt cgacgtggtg   3180

tgcggtgtcg gctacgacca gatcgatccc gagaacccgg catacaagta cctgaacatc   3240

ccccgcgttg tcaccaacct cggtgtcttc gacttcggtg accgggaaa caccttccgc   3300

gcgctgagcc tccatcccgg cgtcaccgcc gaagaggtag ccgagaacac ctcgttcgag   3360

gtagccggac tcgccgaggc cggtatcacc cgtgacccca ccgccgaaga gctccacctc   3420

attcgcgaga ccctcgatcc gcgcaacctt cgggaccgtg aggtctcggc atgacccta   3480

ctctgaagac agcactgacc gaactggtcg gtgtcgagta cccgatcgtg cagacgggca   3540

tgggctgggt ttccgggcca gcgctgacgt cggcgacggc caacgcgggc ggtctcggca   3600

tcctggcttc ggccacgatg acctacgacg agctcgagca cgcgatcaag aagacgaagc   3660

agctcacgga caagccgttc ggtgtcaaca tgcgtgccga cgccaccgac gcgccgcagc   3720

gcgcggacct gctgatccgt gagggcgtca aggtcgcgtc gtttgccttg gctcccaaga   3780

aggaactgat cgccaagctc aaggaccacg gcatcgtcgt cgtaccgtcg atcggtgccg   3840

cgaagcatgc ggtcaaggtt gcatcttggg gcgcggacgc cgtcatcgtc cagggcggcg   3900

aaggtggtgg tcacaccggc ggtgtggcaa cgacattgct tcttccctcg gttctcgacg   3960

cggtcgatat tccggtcatc gccggtggcg gattcttcga cggccgcggg ctggccgcag   4020

cgttggcgta cggcgctgcc ggtgtcgcca tggggacgcg tttcttgctc accagtgact   4080

cttcggtgcc ggactccgtc aagcaggaat acctcaagcg aggactgacg gatacgacgg   4140

tctcgcgcaa ggtcgacggc atgcctcatc gtgtgctcaa caccgacctg gtcaacagcc   4200

tcgaaggttc cagctatgca accggtttga tcgctgctgc caagaacgcc accaagttca   4260

aggcaatgac aggtatgaag tggtcgacgc tcgccaagga                         4300
```

<210> SEQ ID NO 2
<211> LENGTH: 909
<212> TYPE: DNA
<213> ORGANISM: Rhodococcus erythropolis
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(906)
<223> OTHER INFORMATION: ipdA

<400> SEQUENCE: 2

-continued

```
atg gct agc aag cgt gac aag acg aag tcg ctc gac gag gta gtc ggc      48
Met Ala Ser Lys Arg Asp Lys Thr Lys Ser Leu Asp Glu Val Val Gly
1               5                   10                  15

gag ctc cgc agc gga atg acg atc ggc ttg ggc ggc tgg gga tct cgc      96
Glu Leu Arg Ser Gly Met Thr Ile Gly Leu Gly Gly Trp Gly Ser Arg
20                  25                  30

cgc aag ccg atg gcc ttc gtg cgt gcg att ctg cgt tcg gac atc aag     144
Arg Lys Pro Met Ala Phe Val Arg Ala Ile Leu Arg Ser Asp Ile Lys
35                  40                  45

gac ctg acc gtg gtc act tac ggc gga ccg gat ctc ggg ctg ctg tgc     192
Asp Leu Thr Val Val Thr Tyr Gly Gly Pro Asp Leu Gly Leu Leu Cys
50                  55                  60

tcg gcc ggc aag gtc aag aag gcg tac tac ggt ttc gtg tcc ctg gac     240
Ser Ala Gly Lys Val Lys Lys Ala Tyr Tyr Gly Phe Val Ser Leu Asp
65                  70                  75                  80

tcc gct ccg ttc tac gat ccg tgg ttt gcc aag gca cgc acc gcc ggt     288
Ser Ala Pro Phe Tyr Asp Pro Trp Phe Ala Lys Ala Arg Thr Ala Gly
85                  90                  95

gag atc gaa gtc cgc gag atg gac gag gga atg gtc aag tgc ggc ctc     336
Glu Ile Glu Val Arg Glu Met Asp Glu Gly Met Val Lys Cys Gly Leu
100                 105                 110

gaa gcc gct gcc gct cgc ctc cct ttc ctc ccg atc cgc gcg ggc ctg     384
Glu Ala Ala Ala Ala Arg Leu Pro Phe Leu Pro Ile Arg Ala Gly Leu
115                 120                 125

ggt tcg gac gtt cgc aac ttc tgg ggc gac gaa ctc aag acc gtc acc     432
Gly Ser Asp Val Arg Asn Phe Trp Gly Asp Glu Leu Lys Thr Val Thr
130                 135                 140

tcc ccg tac cca gag gcc gac ggc cgt tcc gag acc ttg atc gcg atg     480
Ser Pro Tyr Pro Glu Ala Asp Gly Arg Ser Glu Thr Leu Ile Ala Met
145                 150                 155                 160

cct gca ctc aac ctc gat gcg tcg ttc gtt cac ctc aat ctc ggt gac     528
Pro Ala Leu Asn Leu Asp Ala Ser Phe Val His Leu Asn Leu Gly Asp
165                 170                 175

aag cac ggc aat gcc gcg tac aac ggt gtc gac ccg tac ttc gac gac     576
Lys His Gly Asn Ala Ala Tyr Asn Gly Val Asp Pro Tyr Phe Asp Asp
180                 185                 190

ctg tac tgc atg gcc gcc gaa aag cgt tac gtc tcc gtc gaa cgc att     624
Leu Tyr Cys Met Ala Ala Glu Lys Arg Tyr Val Ser Val Glu Arg Ile
195                 200                 205

gtc gag acc gag gaa ctg gtc aaa tcc gtt cca ctg cag aat ctt ctg     672
Val Glu Thr Glu Glu Leu Val Lys Ser Val Pro Leu Gln Asn Leu Leu
210                 215                 220

ctc aac cgc atg atg gtc gac gcc gtc gtc gag gcc ccg aac ggt gcc     720
Leu Asn Arg Met Met Val Asp Ala Val Val Glu Ala Pro Asn Gly Ala
225                 230                 235                 240

cac ttc acg ttg gcc ggc gaa agc tac ggc cgc gac gag aag ttc cag     768
His Phe Thr Leu Ala Gly Glu Ser Tyr Gly Arg Asp Glu Lys Phe Gln
245                 250                 255

cgt cac tac gcc gag gcc gcc aag acc ccc gag tcg tgg cag acg ttc     816
Arg His Tyr Ala Glu Ala Ala Lys Thr Pro Glu Ser Trp Gln Thr Phe
260                 265                 270

gtc gac acc ttc ctc tcc ggc agc gaa gag gac tac caa gcc gca gta     864
Val Asp Thr Phe Leu Ser Gly Ser Glu Glu Asp Tyr Gln Ala Ala Val
275                 280                 285

aag aag ttt gcc gat tca tca aag gca ggg gag cag gca aaa tga         909
Lys Lys Phe Ala Asp Ser Ser Lys Ala Gly Glu Gln Ala Lys
290                 295                 300
```

-continued

```
<210> SEQ ID NO 3
<211> LENGTH: 302
<212> TYPE: PRT
<213> ORGANISM: Rhodococcus erythropolis

<400> SEQUENCE: 3

Met Ala Ser Lys Arg Asp Lys Thr Lys Ser Leu Asp Glu Val Val Gly
1               5                   10                  15

Glu Leu Arg Ser Gly Met Thr Ile Gly Leu Gly Gly Trp Gly Ser Arg
20                  25                  30

Arg Lys Pro Met Ala Phe Val Arg Ala Ile Leu Arg Ser Asp Ile Lys
35                  40                  45

Asp Leu Thr Val Val Thr Tyr Gly Gly Pro Asp Leu Gly Leu Leu Cys
50                  55                  60

Ser Ala Gly Lys Val Lys Lys Ala Tyr Tyr Gly Phe Val Ser Leu Asp
65                  70                  75                  80

Ser Ala Pro Phe Tyr Asp Pro Trp Phe Ala Lys Ala Arg Thr Ala Gly
85                  90                  95

Glu Ile Glu Val Arg Glu Met Asp Glu Gly Met Val Lys Cys Gly Leu
100                 105                 110

Glu Ala Ala Ala Ala Arg Leu Pro Phe Leu Pro Ile Arg Ala Gly Leu
115                 120                 125

Gly Ser Asp Val Arg Asn Phe Trp Gly Asp Glu Leu Lys Thr Val Thr
130                 135                 140

Ser Pro Tyr Pro Glu Ala Asp Gly Arg Ser Glu Thr Leu Ile Ala Met
145                 150                 155                 160

Pro Ala Leu Asn Leu Asp Ala Ser Phe Val His Leu Asn Leu Gly Asp
165                 170                 175

Lys His Gly Asn Ala Ala Tyr Asn Gly Val Asp Pro Tyr Phe Asp Asp
180                 185                 190

Leu Tyr Cys Met Ala Ala Glu Lys Arg Tyr Val Ser Val Glu Arg Ile
195                 200                 205

Val Glu Thr Glu Glu Leu Val Lys Ser Val Pro Leu Gln Asn Leu Leu
210                 215                 220

Leu Asn Arg Met Met Val Asp Ala Val Val Glu Ala Pro Asn Gly Ala
225                 230                 235                 240

His Phe Thr Leu Ala Gly Glu Ser Tyr Gly Arg Asp Glu Lys Phe Gln
245                 250                 255

Arg His Tyr Ala Glu Ala Ala Lys Thr Pro Glu Ser Trp Gln Thr Phe
260                 265                 270

Val Asp Thr Phe Leu Ser Gly Ser Glu Glu Asp Tyr Gln Ala Ala Val
275                 280                 285

Lys Lys Phe Ala Asp Ser Ser Lys Ala Gly Glu Gln Ala Lys
290                 295                 300


<210> SEQ ID NO 4
<211> LENGTH: 756
<212> TYPE: DNA
<213> ORGANISM: Rhodococcus erythropolis
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(753)
<223> OTHER INFORMATION: ipdB
```

-continued

<400> SEQUENCE: 4

```
atg agc gaa tcc acc gtc acc cgc gca gag tac gtt gtt ctc gcg tgc       48
Met Ser Glu Ser Thr Val Thr Arg Ala Glu Tyr Val Val Leu Ala Cys
1               5                   10                  15

gct gaa atc ttc tcc ggt gca ggc gaa atc atg gcc agc ccg atg tcg       96
Ala Glu Ile Phe Ser Gly Ala Gly Glu Ile Met Ala Ser Pro Met Ser
20                  25                  30

acg tcg tcc acc atc ggc gct cgc ctg gct cgg ctc acc acc gaa ccc      144
Thr Ser Ser Thr Ile Gly Ala Arg Leu Ala Arg Leu Thr Thr Glu Pro
35                  40                  45

gac ctg ctg atc acc gat ggt gaa gcc ctc att ctc gag gac acc ccg      192
Asp Leu Leu Ile Thr Asp Gly Glu Ala Leu Ile Leu Glu Asp Thr Pro
50                  55                  60

gca gtc gga acg aag ggc ccc atc gaa gga tgg atg cct ttc cgc aag      240
Ala Val Gly Thr Lys Gly Pro Ile Glu Gly Trp Met Pro Phe Arg Lys
65                  70                  75                  80

gtg ttc gac gtc gtc gct tcg ggc cgt cgc cac gta gtc atg ggc gcc      288
Val Phe Asp Val Val Ala Ser Gly Arg Arg His Val Val Met Gly Ala
85                  90                  95

aat cag ctc gat cgc cac ggc aac cag aac ctc tcc gcc ttc ggc ccg      336
Asn Gln Leu Asp Arg His Gly Asn Gln Asn Leu Ser Ala Phe Gly Pro
100                 105                 110

ctt cag cag ccg acg cgt cag atg ttc ggt gtg cgc ggc gcc ccg ggc      384
Leu Gln Gln Pro Thr Arg Gln Met Phe Gly Val Arg Gly Ala Pro Gly
115                 120                 125

aac acc atc aac cac gcg acg agc tac ttc gtc ccc aag cac tcc aag      432
Asn Thr Ile Asn His Ala Thr Ser Tyr Phe Val Pro Lys His Ser Lys
130                 135                 140

cga gtg ttc gtc gac aag gtc gac gtg gtg tgc ggt gtc ggc tac gac      480
Arg Val Phe Val Asp Lys Val Asp Val Val Cys Gly Val Gly Tyr Asp
145                 150                 155                 160

cag atc gat ccc gag aac ccg gca tac aag tac ctg aac atc ccc cgc      528
Gln Ile Asp Pro Glu Asn Pro Ala Tyr Lys Tyr Leu Asn Ile Pro Arg
165                 170                 175

gtt gtc acc aac ctc ggt gtc ttc gac ttc ggt gga ccg gga aac acc      576
Val Val Thr Asn Leu Gly Val Phe Asp Phe Gly Gly Pro Gly Asn Thr
180                 185                 190

ttc cgc gcg ctg agc ctc cat ccc ggc gtc acc gcc gaa gag gta gcc      624
Phe Arg Ala Leu Ser Leu His Pro Gly Val Thr Ala Glu Glu Val Ala
195                 200                 205

gag aac acc tcg ttc gag gta gcc gga ctc gcc gag gcc ggt atc acc      672
Glu Asn Thr Ser Phe Glu Val Ala Gly Leu Ala Glu Ala Gly Ile Thr
210                 215                 220

cgt gac ccc acc gcc gaa gag ctc cac ctc att cgc gag acc ctc gat      720
Arg Asp Pro Thr Ala Glu Glu Leu His Leu Ile Arg Glu Thr Leu Asp
225                 230                 235                 240

ccg cgc aac ctt cgg gac cgt gag gtc tcg gca tga                      756
Pro Arg Asn Leu Arg Asp Arg Glu Val Ser Ala
245                 250
```

```
<210> SEQ ID NO 5
<211> LENGTH: 251
<212> TYPE: PRT
<213> ORGANISM: Rhodococcus erythropolis

<400> SEQUENCE: 5

Met Ser Glu Ser Thr Val Thr Arg Ala Glu Tyr Val Val Leu Ala Cys
1               5                   10                  15
```

-continued

```
Ala Glu Ile Phe Ser Gly Ala Gly Glu Ile Met Ala Ser Pro Met Ser
20              25                  30

Thr Ser Ser Thr Ile Gly Ala Arg Leu Ala Arg Leu Thr Thr Glu Pro
35              40                  45

Asp Leu Leu Ile Thr Asp Gly Glu Ala Leu Ile Leu Glu Asp Thr Pro
50              55                  60

Ala Val Gly Thr Lys Gly Pro Ile Glu Gly Trp Met Pro Phe Arg Lys
65              70                  75              80

Val Phe Asp Val Val Ala Ser Gly Arg Arg His Val Val Met Gly Ala
85              90                  95

Asn Gln Leu Asp Arg His Gly Asn Gln Asn Leu Ser Ala Phe Gly Pro
100             105                 110

Leu Gln Gln Pro Thr Arg Gln Met Phe Gly Val Arg Gly Ala Pro Gly
115             120                 125

Asn Thr Ile Asn His Ala Thr Ser Tyr Phe Val Pro Lys His Ser Lys
130             135                 140

Arg Val Phe Val Asp Lys Val Asp Val Val Cys Gly Val Gly Tyr Asp
145             150                 155             160

Gln Ile Asp Pro Glu Asn Pro Ala Tyr Lys Tyr Leu Asn Ile Pro Arg
165             170                 175

Val Val Thr Asn Leu Gly Val Phe Asp Phe Gly Gly Pro Gly Asn Thr
180             185                 190

Phe Arg Ala Leu Ser Leu His Pro Gly Val Thr Ala Glu Glu Val Ala
195             200                 205

Glu Asn Thr Ser Phe Glu Val Ala Gly Leu Ala Glu Ala Gly Ile Thr
210             215                 220

Arg Asp Pro Thr Ala Glu Glu Leu His Leu Ile Arg Glu Thr Leu Asp
225             230                 235             240

Pro Arg Asn Leu Arg Asp Arg Glu Val Ser Ala
245             250
```

```
<210> SEQ ID NO 6
<211> LENGTH: 915
<212> TYPE: DNA
<213> ORGANISM: Rhodococcus erythropolis
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(912)
<223> OTHER INFORMATION: ipdF

<400> SEQUENCE: 6
```

```
atg agt gga ttg gtc gac gga cgc gta gtc atc atc acc ggg gct ggt      48
Met Ser Gly Leu Val Asp Gly Arg Val Val Ile Ile Thr Gly Ala Gly
1               5                   10                  15

cgc ggg atc gga cgt gcg cat gcc ttg gcg ttt gct gcc gag ggc gcc      96
Arg Gly Ile Gly Arg Ala His Ala Leu Ala Phe Ala Ala Glu Gly Ala
20              25                  30

aag gtc gtc gtc aac gac atc ggt gcg ggt gcc gac ggt tcc gag acc     144
Lys Val Val Val Asn Asp Ile Gly Ala Gly Ala Asp Gly Ser Glu Thr
35              40                  45

ggt gag agt ccg gcc gag cag gtt gtc gcg gag atc atc gcc gcc ggt     192
Gly Glu Ser Pro Ala Glu Gln Val Val Ala Glu Ile Ile Ala Ala Gly
50              55                  60

ggc caa gca gtg gtc aac gga gac gac gtc gcc gac tgg gcg ggc gcc     240
Gly Gln Ala Val Val Asn Gly Asp Asp Val Ala Asp Trp Ala Gly Ala
```

65	70	75	80	

```
gag aat ctg atc aag acc gcg atc gac acc ttc ggt ggc ctg gac gta    288
Glu Asn Leu Ile Lys Thr Ala Ile Asp Thr Phe Gly Gly Leu Asp Val
85                  90                  95

ctc gtg aac aac gcg ggc ttc ctg cgg gac cgc atg ctg gtc ggc atg    336
Leu Val Asn Asn Ala Gly Phe Leu Arg Asp Arg Met Leu Val Gly Met
100                 105                 110

agc gaa ggc gag tgg gac gcg gtg att cgc gtg cac ctc aag ggg cac    384
Ser Glu Gly Glu Trp Asp Ala Val Ile Arg Val His Leu Lys Gly His
115                 120                 125

ttc gcg ccg ctg cgt cac gct gct gcc tac tgg cgc gct gag gcc aag    432
Phe Ala Pro Leu Arg His Ala Ala Ala Tyr Trp Arg Ala Glu Ala Lys
130                 135                 140

gca ggc aag acc gtc gac gca cgc atc atc aac acc agt tcg ggt gca    480
Ala Gly Lys Thr Val Asp Ala Arg Ile Ile Asn Thr Ser Ser Gly Ala
145                 150                 155                 160

gga ctg caa ggt tcg atc ggc cag ggt aac tac gct gcg gcg aag gcc    528
Gly Leu Gln Gly Ser Ile Gly Gln Gly Asn Tyr Ala Ala Ala Lys Ala
165                 170                 175

ggt atc gcc gag atg acc atc cag gcc gca gcc gag ctc aag aat tac    576
Gly Ile Ala Glu Met Thr Ile Gln Ala Ala Ala Glu Leu Lys Asn Tyr
180                 185                 190

ggc gtc agt gtc aac gcg atc gcg cct gct gcg cgc acg cgc atg acc    624
Gly Val Ser Val Asn Ala Ile Ala Pro Ala Ala Arg Thr Arg Met Thr
195                 200                 205

gtc ggc gcg ggt ggg gcg atg gcc gag tcg atg gca gct ccc gaa gag    672
Val Gly Ala Gly Gly Ala Met Ala Glu Ser Met Ala Ala Pro Glu Glu
210                 215                 220

ggc ttc gat gcc atg gcg ccc gag aac atc tcg ccg ctg gtc gtc tgg    720
Gly Phe Asp Ala Met Ala Pro Glu Asn Ile Ser Pro Leu Val Val Trp
225                 230                 235                 240

ctc ggt agc gcc gag tcc aag gac gtc acg ggg cgg gtg ttc gag gtc    768
Leu Gly Ser Ala Glu Ser Lys Asp Val Thr Gly Arg Val Phe Glu Val
245                 250                 255

gag ggc gga aag atc acc gtc gcg gag ggc tgg cgt cac ggc ccg agc    816
Glu Gly Gly Lys Ile Thr Val Ala Glu Gly Trp Arg His Gly Pro Ser
260                 265                 270

gag gac aag ggt gac cgt tgg gac ccg aag gag atc ggg ccc gtc gtg    864
Glu Asp Lys Gly Asp Arg Trp Asp Pro Lys Glu Ile Gly Pro Val Val
275                 280                 285

gca acg ctg ttg gag aag gcg gag att ccg acg ccg gtg tac gga gcg    912
Ala Thr Leu Leu Glu Lys Ala Glu Ile Pro Thr Pro Val Tyr Gly Ala
290                 295                 300

tag                                                                915
```

```
<210> SEQ ID NO 7
<211> LENGTH: 304
<212> TYPE: PRT
<213> ORGANISM: Rhodococcus erythropolis

<400> SEQUENCE: 7

Met Ser Gly Leu Val Asp Gly Arg Val Val Ile Ile Thr Gly Ala Gly
1               5                   10                  15

Arg Gly Ile Gly Arg Ala His Ala Leu Ala Phe Ala Ala Glu Gly Ala
20              25                  30

Lys Val Val Val Asn Asp Ile Gly Ala Gly Ala Asp Gly Ser Glu Thr
35              40                  45
```

-continued

```
Gly Glu Ser Pro Ala Glu Gln Val Val Ala Glu Ile Ile Ala Ala Gly
50              55                  60

Gly Gln Ala Val Val Asn Gly Asp Asp Val Ala Asp Trp Ala Gly Ala
65                  70                  75                  80

Glu Asn Leu Ile Lys Thr Ala Ile Asp Thr Phe Gly Gly Leu Asp Val
85                  90                  95

Leu Val Asn Asn Ala Gly Phe Leu Arg Asp Arg Met Leu Val Gly Met
100                 105                 110

Ser Glu Gly Glu Trp Asp Ala Val Ile Arg Val His Leu Lys Gly His
115                 120                 125

Phe Ala Pro Leu Arg His Ala Ala Ala Tyr Trp Arg Ala Glu Ala Lys
130                 135                 140

Ala Gly Lys Thr Val Asp Ala Arg Ile Ile Asn Thr Ser Ser Gly Ala
145                 150                 155                 160

Gly Leu Gln Gly Ser Ile Gly Gln Gly Asn Tyr Ala Ala Ala Lys Ala
165                 170                 175

Gly Ile Ala Glu Met Thr Ile Gln Ala Ala Ala Glu Leu Lys Asn Tyr
180                 185                 190

Gly Val Ser Val Asn Ala Ile Ala Pro Ala Ala Arg Thr Arg Met Thr
195                 200                 205

Val Gly Ala Gly Gly Ala Met Ala Glu Ser Met Ala Ala Pro Glu Glu
210                 215                 220

Gly Phe Asp Ala Met Ala Pro Glu Asn Ile Ser Pro Leu Val Val Trp
225                 230                 235                 240

Leu Gly Ser Ala Glu Ser Lys Asp Val Thr Gly Arg Val Phe Glu Val
245                 250                 255

Glu Gly Gly Lys Ile Thr Val Ala Glu Gly Trp Arg His Gly Pro Ser
260                 265                 270

Glu Asp Lys Gly Asp Arg Trp Asp Pro Lys Glu Ile Gly Pro Val Val
275                 280                 285

Ala Thr Leu Leu Glu Lys Ala Glu Ile Pro Thr Pro Val Tyr Gly Ala
290                 295                 300


<210> SEQ ID NO 8
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: P1 (XbaI) Forward primer

<400> SEQUENCE: 8

gcgtctagac tgcgagccga gggacgcg                                    28


<210> SEQ ID NO 9
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: P2 (BamHI) reverse primer

<400> SEQUENCE: 9

gcgggatccg tccgaacgca gaatcgcacg                                  30


<210> SEQ ID NO 10
<211> LENGTH: 29
```

-continued

```
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: P3 (BamHI) forward primer


<400> SEQUENCE: 10

gcgggatccc tcgccgaggc cggtatcac                                29


<210> SEQ ID NO 11
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: P4 (SmaI) reverse primer


<400> SEQUENCE: 11

gcgggatccc tcgccgaggc cggtatcac                                29


<210> SEQ ID NO 12
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: IpdF-F forward primer


<400> SEQUENCE: 12

atacatatga gtggattggt cgacggac                                 28


<210> SEQ ID NO 13
<211> LENGTH: 31
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: IpdF-R reverse primer


<400> SEQUENCE: 13

ataggatccc tacgctccgt acaccggcgt c                            31
```

1. A method to construct a genetically modified strain of a steroid-degrading micro-organism, wherein the method comprises inactivation of at least one gene involved in methyl-hexahydroindanedione propionate degradation.

2. The method according to claim 1, wherein the method comprises inactivation of multiple genes involved in methyl-hexahydroindanedione propionate degradation.

3. The method according to claim 1, wherein at least one gene encoding a HIP CoA transferase is inactivated.

4. The method according to claim 3, wherein the HIP CoA transferase genes ipdA and ipdB are inactivated.

5. The method according to claim 1 wherein a gene encoding a HIL-(3'α-hydroxypropionyl)-CoA dehydrogenase (ipdF) is inactivated.

6. The method according to claim 1, wherein any gene is inactivated by UV-irradiation.

7. The method according to claim 1, wherein any gene is deleted by unmarked gene deletion.

8. The method according to claim 1, wherein the micro-organism belongs to the family of Actinomycetesis.

9. The method according to claim 8, wherein the micro-organism belongs to the genus *Rhodococcus*.

10. The method according to claim 9, wherein the micro-organism is *Rhodococcus erythropolis*.

11. A genetically modified strain of a micro-organism prepared according to claim 1.

12. The genetically modified strain a-cording to claim 11 being *Rhodococcus erythropolis* RG37.

13. The genetically modified strain according to claim 11, being *Rhodococcus erythropolis* RG33.

14. A method for preparing a steroid intermediate, the method comprising

(a) preparing a genetically modified strain of a steroid-degrading micro-organism, which comprises inactivation of at least one gene involved in methylhexahydroindanedione propionate degradation; and

b) adding a steroid starting material to the genetically modified strain of step (a).

15. The method according to claim 14, wherein the steroid intermediate is 3aα-H-4α(3'-propionic acid)-7aβ-methyl-hexahydro-1,5-indanedione (HIP) and/or 3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione (3-HSA) and the steroid starting material is 9α-hydroxy-4-androstene-3,17-dione (9OHAD).

16. The method according to claim 14, wherein the steroid intermediate is 1,4-androstadiene-3,17-dione (ADD) and the steroid starting material is 4-androstene-3,17-dione (AD).

17. The method according to claim **14**, wherein the steroid intermediate is 3aα-H-4α(3'-propionic acid)-5α-hydroxy-7aβ-methylhexahydro-1-indanone-δ-lactone (HIL) and the steroid starting material is 4-androstene-3,17-dione (AD).

18. An IpdA protein comprising the amino acid sequence SEQ ID NO:3 or orthologues therefrom.

19. An IpdB protein comprising the amino acid sequence SEQ ID NO:5 or orthologues therefrom.

20. An IpdF protein comprising the amino acid sequence SEQ ID NO:7 or orhologues therefrom.

21. The DNA sequence encoding an IpdA protein according to claim **18**.

22. The DNA sequence encoding an IpdB protein according to claim **19**.

23. The DNA sequence encoding an IpdF protein according to claim **20**.

24. A DNA sequence comprising nucleotides 1814-2722 of SEQ ID NO:1.

25. A DNA sequence comprising nucleotides 2719-3474 of SEQ ID NO:1.

26. A DNA sequence comprising nucleotides 927-13 of SEQ ID NO:1.

* * * * *